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Abstract
The most important mechanism for b-lactam resistance in b-lactamase-negative ampicillin-resistant (BLNAR) isolates of Haemophilus
inﬂuenzae is the alteration of penicillin-binding protein 3 (PBP3) as a result of ftsI gene mutations. The present study aimed to map
PBP3 alterations and to determine the correlation to b-lactam resistance in respiratory tract isolates of H. inﬂuenzae in Norway, as well
as assess the contribution of clonal spread to the emergence of PBP3-mediated resistance. Twenty-three b-lactamase negative respira-
tory tract isolates with resistance to penicillins and 23 susceptible control isolates were examined by determination of b-lactam MICs,
ftsI sequencing and molecular typing by pulsed-ﬁeld gel electrophoresis (PFGE). Ampicillin MIC ranges in the resistant group and the
control group were 1–2 mg/L and 0.125–0.5 mg/L, respectively. All isolates in the resistant group had the PBP3 substitution Asn526 ﬁ
Lys and were thus categorized as group II low-BLNAR. No control isolate met the genetic BLNAR (gBLNAR) criteria. The PBP3
substitution patterns corresponded well to those observed in previous European studies. Eighty-three percent (19/23) of the resistant
isolates belonged to two clones, demonstrating the capability of low-BLNAR strains of clonal dissemination. Combined analysis of ftsI
DNA sequences and PFGE patterns revealed distinctly different ftsI alleles in genetically indistinguishable isolates and identical copies of
the same ftsI allele in unrelated isolates. A possible explanation of this observation is the recombinational exchange of ftsI alleles. This
phenomenon, as well as the possibility of endemic European gBLNAR strains, should be further investigated.
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Introduction
Resistance to aminopenicillins in Haemophilus inﬂuenzae is
most commonly caused by plasmid-mediated b-lactamases, of
which two types, TEM-1 [1] and ROB-1 [2], have been char-
acterized. The most important b-lactam resistance mecha-
nism in b-lactamase-negative ampicillin-resistant isolates
(BLNAR) is alteration of penicillin-binding protein 3 (PBP3),
leading to decreased afﬁnity to penicillins and cephalosporins
[3], as a result of ftsI gene mutations resulting in amino acid
substitutions in the transpeptidase domain of PBP3 [4].
The originally phenotypic term BLNAR is also part of a
genetically based classiﬁcation system for H. inﬂuenzae iso-
lates with PBP3-mediated b-lactam resistance. According to
Ubukata et al. [4], isolates with the substitutions Arg517 ﬁ
His or Asn526 ﬁ Lys near the Lys-Thr-Gly (KTG) motif are
designated group I and group II BLNAR, respectively,
whereas isolates possessing the substitutions Met377 ﬁ Ile,
Ser385 ﬁ Thr and Leu389 ﬁ Phe near the Ser-Ser-Asn
(SSN) motif in addition to Asn526 ﬁ Lys are designated
group III BLNAR. A system for subgrouping of group II iso-
lates according to amino acid substitution patterns was intro-
duced by Dabernat et al. [5]. Simpliﬁcations of the
classiﬁcation system have been suggested by Hasegawa et al.
[6], who deﬁned isolates with only KTG-near substitutions
as low-BLNAR and isolates with both KTG- and SSN-near
substitutions as BLNAR, as well as by Hotomi et al. [7], who
introduced the term genetic BLNAR (gBLNAR) as a common
description for group I, II and III BLNAR isolates.
Genotyping by pulsed-ﬁeld gel electrophoresis (PFGE) is
useful for epidemiological typing of H. inﬂuenzae [8]. How-
ever, previous studies have indicated that gBLNAR isolates in
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general are genetically diverse and that clonal expansion,
with few exceptions [6,7,9], is limited or absent [5,10–12].
The present study aimed: (i) to map PBP3 alterations in
respiratory tract isolates of H. inﬂuenzae in Norway and to
determine the correlation to b-lactam resistance by compar-
ing the amino acid sequences of susceptible and resistant iso-
lates and (ii) to assess the contribution of clonal spread to
the emergence of PBP3-mediated resistance.
To our knowledge, this is the ﬁrst study providing infor-
mation about PBP3 alterations and the molecular epidemiol-
ogy of Nordic H. inﬂuenzae isolates.
Materials and Methods
Study isolates
Twenty-three H. inﬂuenzae isolates with phenotypic character-
istics indicating non-b-lactamase-mediated b-lactam resistance
(resistant group) and 23 isolates with wild-type susceptibility
to penicillins (control group) were included. All isolates were
taken from a collection of 484 respiratory tract isolates from
patients with respiratory tract, ear and eye infections between
January and March 2004 as part of the Norwegian Surveillance
Programme for Antimicrobial Resistance (NORM) [13]. The
selection of isolates was based on previous susceptibility test-
ing performed at the respective primary laboratories. For the
resistant group, isolates ﬁtting one or more of three criteria
were selected: (i) b-lactamase negative and ampicillin MIC ‡ 2
mg/L; (ii) amoxicillin-clavulanate MIC ‡ 4 mg/L; and/or (iii)
b-lactamase negative and penicillin G MIC ‡ 8 mg/L. For each
resistant isolate, the ﬁrst consecutive susceptible isolate from
the same laboratory was included in the control group.
Isolates accepted as controls had MICs within the ranges:
ampicillin MIC = 0.125–0.5 mg/L, amoxicillin-clavulanate
MIC = 0.25–1 mg/L and penicillin G MIC = 0.25–1 mg/L.
The isolates were kept frozen at )70C at the primary labo-
ratories. When received at the study laboratory, the isolates
were plated on chocolate agar and incubated for 24 h at
35 ± 1C in 5% CO2. After visual control of purity, the iso-
lates were conﬁrmed as H. inﬂuenzae by their requirement of
b-NAD+ (V factor) and haemin (X factor) for growth. Capsu-
lar types were determined using a slide agglutination test with
speciﬁc a to f antisera (Remel Europe Ltd, Dartford, UK). The
isolates were refrozen at )70C in Microbank (Pro-Lab Diag-
nostics, Richmond Hill, Ontario, Canada) vials until susceptibil-
ity testing and molecular procedures were performed.
Susceptibility testing
Testing for b-lactamase production was carried out with the
chromogenic cephalosporin nitroceﬁn (Oxoid Ltd, Basingstoke,
UK) as the substrate. Determination of the MICs of ampicillin,
cefuroxime, cefotaxime, ceftriaxone and meropenem was
made with the Etest (AB Biodisk, Solna, Sweden) according to
the manufacturer’s instructions, using Mueller–Hinton agar
enriched with 1% haemoglobin and 1% BBL IsoVitaleX
Enrichment (Becton Dickson, Franklin Lakes, NJ, USA).
The reference strains H. inﬂuenzae ATCC 49247 (BLNAR
phenotype) and H. inﬂuenzae ATCC 49766 (ampicillin
susceptible) were used as controls for the susceptibility test-
ing procedures.
PCR and DNA sequencing
Five to ten fresh colonies were suspended in 0.5 mL of 0.9%
sterile saline and DNA was isolated from 0.2 mL of the sus-
pension using MagNA Pure LC and the TNAI extraction kit
(Roche, Basel, Switzerland). A 770-bp segment of the ftsI gene,
nucleotides 991–1761, was ampliﬁed using the primers SSNF2
(5¢-CCT TTC GTT GTT TTA ACC GCA-3¢) and KTGR2 (5¢-
AGC TGC TTC AGC ATC TTG-3¢), based on the ftsI
sequence of H. inﬂuenzae Rd KW20 (GenBank accession no.
U32793) [14]. PCR was performed, using the LightCycler
(Roche), in a volume of 20 lL containing 1 · LightCycler
Faststart DNA Master SYBR green I (Roche), 0.5 lM of each
primer and 5 lL of sample DNA. The PCR program com-
prised: polymerase activation, 95C for 10 min followed by
45 cycles of 95C for 10 s, and 45C for 20 s. PCR ampli-
cons were puriﬁed using the QIAEX II agarose gel extrac-
tion kit (Qiagen, Hilden, Germany) after separation in a
1.5% agarose gel. Direct sequencing of the puriﬁed PCR
products with the primers SSNF2 and KTGR2 was per-
formed at GATC Biotech AG (Konstanz, Germany). Analysis
of nucleotide sequences was performed using Lasergene
software (DNASTAR, Madison, WI, USA). Phylogenetic
trees were constructed using distance methods with Haemo-
philus parainﬂuenzae (GenBank accession no. AB267856) [15]
as outgroup and displayed using Treeview software, version
1.6.6 (University of Glasgow, Glasgow, UK). The amino acid
sequences of the transpeptidase region of PBP3 (338–573)
were deduced from the nucleotide sequences and compared
with H. inﬂuenzae Rd KW20.
PFGE analysis
Six to eight colonies were suspended in 5 mL 0.9% sterile
saline to a 3 McFarland standard, harvested by centrifugation
at 5400 g for 10 min, resuspended in 800 lL of 1 M NaCl,
10 mM Tris–HCl (pH 8.0), 0.2% sucrose, containing 10 mg
of lysozyme (Sigma, St Louis, MO, USA), and incubated on
ice for 15 min. The suspension was mixed with an equal vol-
ume of 2% agarose solution in 1 M NaCl, 10 mM Tris–HCl
(pH 8.0) and dispensed into plug moulds. The plugs were
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incubated in 0.5% N-lauryl sarcosine, 0.4 mg/L lysozyme and
5 mg/L RNase in 6 mM Tris–HCl (pH 8.0), 10 mM EDTA
(pH 8.0), 0.2% deoxycholate for 1 h at 37C, then in 0.5 M
EDTA (pH 8.0), 1% N-lauryl sarcosine, 1 g/L proteinase K
(Promega, Madison, WI, USA) for 1 h at 50C. Plugs were
washed with water ﬁve times for 15 min at 55C and stored
at 4C in 1 · TE-buffer (pH 8.0). SmaI (Promega) digestion
and PFGE was performed as described previously [5]. Staphy-
lococcus aureus NCTC 8325 DNA was used as size standard
[16]. The software GelCompare II (Applied Maths, Sint-
Martens-Latem, Belgium) was used for calculating Dice coefﬁ-
cients of similarity and for generating a dendrogram by the
unweighted pair group method with arithmetic means.
Nucleotide sequence accession numbers
The ftsI sequences of the study isolates and reference strains
were deposited in the EMBL Nucleotide Sequence Database
under accession numbers FM161990 and FM163633 to
FM163679.
Results
Characteristics of study isolates
The 46 study isolates were collected from 15 different labo-
ratories, representing 12 out of 19 Norwegian counties. All
isolates were from different patients. Nine out of 23 resis-
tant isolates and ten of 23 control isolates were from hospi-
talized patients. The median ages in the resistance group and
the control group were 14 (<1–86) and 12 (<1–77) years
and the male : female ratios were 9 : 14 and 10 : 13, respec-
tively. Upper respiratory tract isolates predominated in both
the resistance group (n = 11) and in the control group
(n = 14). Lower respiratory tract isolates were more fre-
quent in the resistance group (n = 5) than in the control
group (n = 2), whereas middle ear isolates were only present
in the control group (n = 4). The remaining isolates in the
resistance group (n = 7) and the control group (n = 3) were
respiratory tract isolates of nonspeciﬁed origin. All isolates
were non-encapsulated.
Susceptibility to b-lactams
All isolates were b-lactamase-negative according to the nitr-
oceﬁn test. The resistance levels to all b-lactams, according
to MIC50 and MIC90 determinations, were increased for the
isolates in the resistant group compared to the control iso-
lates (Table 1). No isolates met the original phenotypic
BLNAR criterion of ampicillin MIC ‡ 4 mg/L [17] but the
ampicillin MICs for 52% (12/23) of the isolates in the resis-
tant group were 2 mg/L, which were thus nonsusceptible to
this agent according to both European Committee on Anti-
microbial Susceptibility Testing (EUCAST) [18] and CLSI
breakpoints [19]. The greatest difference between the two
groups was observed for cefuroxime, the MIC90 of which for
the resistant group was 16-fold greater than the MIC90 for
the control group. Ninety-six percent (22/23) and 83% (19/
23) of the isolates in the resistant group were nonsusceptible
to cefuroxime according to EUCAST and CLSI breakpoints,
respectively (data not shown). All isolates in both groups
were susceptible to cefotaxime, ceftriaxone and meropenem.
For both ATCC reference strains, the MICs of all agents
were within the acceptable limits as determined by CLSI
criteria [19].
Amino acid substitutions in PBP3
Sequence analysis revealed a total of 12 amino acid substitu-
tions relative to H. inﬂuenzae Rd KW20 in ten positions
between amino acids 338 and 573 in PBP3 (Table 1). No
previously unreported substitution was observed. The gBL-
NAR deﬁning substitution Asn526 ﬁ Lys was detected in all
isolates in the resistant group, categorizing them as group II
low-BLNAR [4,6]. Six different substitution patterns denoted
PBP3 substitution types A–F, with from one to seven substi-
tutions, were observed in resistant isolates. Types A
(n = 11) and B (n = 7) were the most prevalent, together
accounting for 78% (18/23) of the isolates in the resistant
group. Two isolates had substitution type C, whereas each
of the three substitution types D–F were present in single
isolates. Types A and C corresponded to BLNAR subgroup
IIb, type B corresponded to subgroup IId and types E and F
corresponded to subgroups IIc and IIa, respectively [5].
Substitution type D and substitution type G of the
BLNAR reference strain ATCC 49247 did not correspond
to any recognized subgroup. None of the control isolates
met the gBLNAR criteria. Forty-four percent (10/23) of
these isolates had the prototype amino acid sequence, des-
ignated PBP3 substitution type z. In the remaining 13 con-
trol isolates, ﬁve different substitution types, denoted U–Y,
with from one to four amino acid substitutions, were
observed.
Comparison of ftsI DNA sequences
Fig. 1 shows a phylogram of the ftsI DNA sequences. There
were thirteen DNA alleles associated with susceptibility. The
majority of these sequences belonged to a cluster of closely-
related sequences including the sequence of the susceptible
reference strain ATCC 49766, hereafter referred to as the
prototype cluster, whereas four alleles (isolates S60, S06,
S44 and S24) were markedly divergent. Four susceptible
sequence alleles (Y1, Y2, z1 and z2) occurred in more than
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two isolates. These were all members of the prototype clus-
ter. There were seven alleles associated with resistance
(including that of the BLNAR reference strain ATCC 49247),
each corresponding to a different amino acid sequence, and
therefore referred to here by letters (A–G) according to
their respective PBP3 substitution type (Table 1). Alleles E
and F belonged to the prototype cluster. Alleles A and C
were highly divergent, whereas alleles B, D and G (the latter
carried by ATCC 49247) were of intermediate divergence
but distinct from the prototype cluster. All alleles found in
multiple isolates (alleles A, B and C) were of divergent type.
Clonal analysis by PFGE
PFGE analysis (Fig. 2) identiﬁed ﬁve clusters, hereunder
called clonal groups 1–5, having 2–12 members with ‡80%
similarity (Dice coefﬁcients) and a maximum of ﬁve band dif-
ferences [16]. Clonal groups 1 (n = 12) and 2 (n = 7)
included only resistant isolates, clonal group 3 (n = 4) con-
tained one resistant and three susceptible isolates and clonal
group 4 (n = 2) contained only susceptible isolates. Clonal
group 5 contained two isolates, with one of these being the
reference strain ATCC 49766 that is not discussed further.
Clonal groups 1–4 comprised 87% (20/23) of the resistant
isolates and only 22% (5/23) of the susceptible control iso-
lates. Clonal groups 1 and 2 alone comprised 83% (19/23) of
the resistant isolates. The members of clonal groups 1 and 2
were geographically widespread, with distances of up to 970
and 410 km, respectively, between domiciles of the corre-
sponding patients.
Comparison of clonal analysis and ftsI alleles
All members of clonal group 2 carried identical copies of
allele B, conﬁrming their close genetic relationship. Clonal
groups 1, 3 and 4, on the other hand, all included isolates
with alleles distinctly different from those of the other mem-
bers of the group. Clonal group 3 contained three suscepti-
ble isolates (isolates S04, S30 and S36) with identical copies
of allele Y1, whereas the fourth and only resistant member
of the group (isolate R03) carried allele D, which differs from
allele Y1 by 34 nucleotide substitutions. Clonal group 4 con-
A
C
B
D
F
E
G
Y2
Y1
z2
z1
FIG. 1. Neighbour-joining rectangular phylogram of ftsI DNA sequences using the distance method. The outgroup (hpa) is Haemophilus parainﬂu-
enzae (AB267856) [15]. The scale is DNA sequence divergence, 0.1 corresponding to 10% divergence. Labelling indicates resistance category (R,
resistant; S, susceptible), isolate identiﬁcation number, pulsed-ﬁeld gel electrophoresis-based clonal group membership (1–5 or ‘x’ where no clo-
nal afﬁnity is observed) and penicillin-binding protein 3 substitution type (in brackets); A–G for resistant isolates, U–z for susceptible isolates,
where z represents the amino acid sequence of Haemophilus inﬂuenzae Rd KW20 [14]. Allele designations used in the text are indicated by
labelled vertical lines to the right of the strains to which they refer.
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tained two isolates (isolates S06 and S26) with alleles differ-
ing by 21 nucleotide substitutions. Clonal group 1 contained
twelve isolates, eleven of which carried identical copies of
allele A, whereas the twelfth isolate (R41) carried allele
C, which differs from allele A by 23 nucleotide substitutions.
Allele C was also found in isolate R21, which had an
unrelated PFGE band pattern.
Discussion
The genetically based classiﬁcation system is useful for the
conﬁrmation of PBP3-mediated b-lactam resistance and for
distinguishing isolates with high-level resistance from the more
commonly occurring isolates with low-level resistance. The
system is still being developed and, in a review by Tristram
et al. [17], it was suggested that any of the three substitutions,
Met377 ﬁ Ile, Leu389 ﬁ Phe or Ala502 ﬁ Val, should be
regarded as a marker of high-level resistance (group III
BLNAR), irrespective of the presence of Ser385 ﬁ Thr.
This is only partially consistent with the results of the
present study. The substitutions Met377 ﬁ Ile and
Ala502 ﬁ Val were both present in substitution types A and
C, which conform to previously published deﬁnitions of the
low-BLNAR subgroup IIb [4–6]. These isolates had ampicillin
MICs within the low-BLNAR range [17] but slightly higher
cephalosporins MICs than type B isolates (subgroup IId),
which lack the aforementioned substitutions. However, the
type B isolates had meropenem MIC90 two dilution steps
higher than the type A isolates.
FIG. 2. Dendrogram showing pulsed-ﬁeld gel
electrophoresis band patterns. Clustering is
according to Dice coefﬁcients of similarity.
The dashed line represents 80% similarity.
Clonal groups are boxed and resistant iso-
lates are in bold. For detailed explanation of
labelling, see Fig. 1.
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The PBP3 substitution patterns in the present study are
similar to the previously reported substitution patterns of
European gBLNAR isolates [5,11,12,20] but differ from the
patterns seen in low-BLNAR isolates from other geographi-
cal regions [4,21,22]. A possible explanation for this differ-
ence might be local clonal dissemination of resistant strains.
However, most previous studies have concluded that clonal
spread is limited or absent [5,10–12]. Thus, we were sur-
prised to ﬁnd that clonal groups 1 and 2 represented 83%
(19/23) of the isolates in the resistant group, a degree of clo-
nality previously unreported in low-BLNAR isolates.
Whether the predominance of these two clones represents
clonal outbreaks or the dissemination of endemic strains
[16] will be investigated further in a future study.
Comparison of the ftsI alleles (Fig. 1) and PFGE band pat-
terns (Fig. 2) revealed another interesting feature because
both clonal groups 1 and 3 included single isolates (isolates
R41 and R03, respectively), with ftsI alleles being distinctly dif-
ferent from those of the remaining isolates. Furthermore, two
genetically unrelated isolates (isolates R21 and R41) possessed
identical copies of ftsI allele C. These observations, together
with the similar ﬁndings obtained in previous studies
[5,11,15], are suggestive of recombinational exchange of ftsI
alleles in vivo. This hypothesis is supported by the recent dem-
onstration of in vitro horizontal transmission of ftsI gene
sequences from a resistant to a susceptible H. inﬂuenzae strain
[15]. However, the small number of isolates in the present
study does not allow any ﬁrm conclusions to be made and we
cannot rigorously exclude the possibility that an unusual com-
bination of mutational changes underlies our observations. A
larger study to further investigate this is underway.
In conclusion, the present study provides evidence indicat-
ing that clonal dissemination contributes to the emergence
of PBP3-mediated b-lactam resistance in H. inﬂuenzae. Fur-
ther studies of the molecular epidemiology of gBLNAR iso-
lates from different European countries should be performed
to identify endemic resistant strains.
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